treatment of epilepsy Flashcards

1
Q

Epilepsy epidemiology

A

Bimodal age distribution: < 1y and > 60y

Mean age of onset = 11.1y

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Mortality risk of epilepsy

A
Increased 2-3 fold 
Highest within first 12m in diagnosis 
Sudden Unexplained Death in Epilepsy (SUDEP) 
Status epilepticus 
Unintentional injuries 
Suicide
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Characteristics of SUDEP

A

Peak at 20-40y
Mostly unwitnessed and sleep related
Risk factors: Presence and frequency of generalised tonic-clonic seizures; nocturnal seizures; lack of seizure freedom

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Seizure definition

A

Transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Epilepsy definition

A

Any of:

  • At least 2 unprovoked seizures occurring > 24h apart
  • One unprovoked seizure and a probability of further seizures similar to the general recurrence risk (at least 60%) after two unprovoked seizures, occurring over the next 10y
  • Diagnosis of an epilepsy syndrome
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Provoked seizures (Acute symptomatic seizure)

A

Events occurring in close temporal relationship with an acute CNS insult with varying intervals according to underlying condition

  • metabolic
  • toxic
  • structural
  • infectious
  • inflammation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Pathophysiology

A

Hyperexcitability and hypersynchronisation
Can be traced back to instability in a single neuronal cell membrane or group of cells around it
Synchronised paroxysmal discharges occurring in a large population of neurons within the cortex

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Causes of hyperexcitability

A

Voltage/ligand-gated K+, Na+, Ca2+ and Cl- ion channels
Abnormalities in intra/extracellular substances
Excessive excitatory neurotransmitters
Insufficient inhibitory neurotransmitters

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Etiology of epilepsy

A
Genetics
Structural
Metabolic
Immune 
Infectious
Unknown
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Classification of seizures

A

Based on mode of onset:
- Focal onset (begins in one hemisphere)
- Generalised onset (begins in both hemispheres)
Impairment of consciousness (with or without dyscognitive features)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Generalised tonic-clonic (grand-mal) seizures

A

Stiffening of limbs (tonic phase), then jerking of limbs and face (clonic phase)
Clonic phase lasts 1min
Incontinence with biting of tongue or inside of mouth
May have headache and appear lethargic, confused or sleepy after seizure
Full recovery takes several minutes to hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Generalised clonic seizures

A

Clonic jerking that is asymmetrical and irregular

Most common in neonates, infants or young children

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Generalised tonic seizures

A

Sudden loss of consciousness and rigid posture of entire body, lasting 10-20s
Occurs at all ages, associated with diffuse cerebral damage and learning disabilities
Characteristic and defining in Lennox-Gastaut syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Generalised myoclonic seizures

A

Rapid, brief contractions of bodily muscles, usually on both sides concurrently
May involve just one arm or one foot

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Generalised absence (petit mal) seizures

A

Basic lapse in awareness that begins and ends abruptly
Lasts only a few seconds, no warning, no after-effects
Often undetected
More common in children, 4-12y

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Differences between generalised absence and complex partial seizures

A

Never preceded by auras
Lasts seconds
Begin frequently and end abruptly
Produce characteristic EEG pattern “3Hz spike waves”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Generalised atonic seizures

A

Classic drop attack, all postural tone suddenly lost
Short episode followed by immediate recovery
Occurs at any age, associated with diffuse cerebral damage and learning disabilities
Common in severe symptomatic epilepsies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Risk of seizure recurrence

A

Within the next 5y: ~30%, higher in the 1st 2y
Higher risk in the presence of:
- epileptic abnormalities on EEG
- prior brain insult
- structural abnormality in brain imaging
- nocturnal seizure
Risk of recurrent seizures after 2 unprovoked seizures at 4y ~70%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

When is treatment not initiated?

A
First unprovoked seizure
None of the following:
- epileptic abnormalities on EEG 
- prior brain insult 
- structural abnormality in brain imaging 
- nocturnal seizure
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Treatment goals

A

Absence of epileptic seizures
Absence of ASM-related side effects
Attainment of optimal QOL
2/3 can achieve seizure freedom

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Non pharmacological treatment

A

Keto diet
Vagus nerve stimulation
Responsive neurostimulator system
Surgery

22
Q

Factors for ASM choice

A

Seizure type, epilepsy syndrome

Co-medication and comorbidities

23
Q

Advantages of monotherapy

A
Likely lower incidence of AE
Easier to correlate response and AE 
Absence of DI
Reduced risk of birth defects 
Lower cost 
Better adherence
24
Q

Initiation of treatment with 1st line ASM

A

Start with low dose of 1st line appropriate ASM
Gradually increase dose if not seizure free and no SE
Review of diagnosis and medication of max tolerated dose; check adherence

25
Q

If failure of therapy

A

Substitution if AE or not tolerated at low doses or no improvement
Combination if tolerated first/second gen ASM but with suboptimal response

26
Q

Seizure triggers

A
Hyperventilation 
Photostimulation 
Physical and emotional stress
Sleep deprivation 
Electrolytes imbalance 
Sensory stimuli
Infection 
Hormonal changes 
Drugs
27
Q

Investigations

A
MRI with gadolinium for: 
- adult patients who presents with first seizure
- pts with focal neurologic deficits 
- suggestion of focal onset seizure 
Biochemical/toxicology
28
Q

Treatment options for new onset focal onset epilepsy

A
A - Carbamazepine*
A - Levetiracetam*
A - Phenytoin
A (E) - Lamotrigine* 
A (E) - Gabapentine 
B - Valproate*
C - Topiramate
A - Zonisamide
29
Q

Treatment options for new onset generalised tonic clonic epilepsy

A

Carbamazepine*
Lamotrigine*
Valproate*
Topiramate

30
Q

Treatment options for refractory focal onset epilepsy

A

Clobazam
Lacosamide
Pregabalin
Perampanel

31
Q

Treatment options for refractory generalised tonic clonic epilepsy

A

Clobazam

Levetiracetam

32
Q

Considerations in epilepsy treatment

A

Migraine - topiramate, valproate
Depression/anxiety - use levetiracetam with caution
Women w child-bearing potential - avoid valproate consider levetiracetam/lamotrigine

33
Q

1st generation AEM

A
Carbamazepine
Phenobarbitone/Phenobarbital 
Phenytoin
Sodium Valproate 
Primidone
34
Q

2nd generation AEM

A
Gabapentin
Lamotrigine
Levetiracetam 
Pregabalin
Topiramate
Clobazam 
Vigabatrin
35
Q

1st gen AEM PK

A

Highly protein bound
Hepatic elimination
Many DDI

36
Q

2nd gen AEM PK

A

Reduced protein binding
Mostly renal elimination except lamotrigine
Fewer (no) DDI except lamotrigine

37
Q

1st gen AEM effects on metabolism

A

Inducers: carbamazepine, phenytoin, phenobarbital
Inhibitor: valproate

38
Q

Issues with enzyme-inducing ASMs

A
DDI
- antidepressants and antipsychotics
- immunosuppressive therapy 
- antiretroviral therapy 
- chemotherapeutic agents 
Reproductive hormone, sexual function, OCPs 
Sexual function and fertility in men 
Bone health
Vascular risk
39
Q

Phenytoin

A
Slow but complete absorption, reduced at higher (>400mg) doses, NGT and feeds interactions 
Highly albumin bound 
Zero-order kinetics 
Capacity limited clearance
AE: osteomalacia
40
Q

Valproate

A

F = 1.0
Highly albumin bound; saturable protein binding with higher conc
Competition with binding: PHT, warfarin, NSAIDs
AE: NV, weight gain, alopecia

41
Q

Carbamazepine

A

Not available in IV formulation
F = 0.8
Highly protein bound
3A4 metabolised
Autoinduction; max 2-3w after dose initiation
Not to be started at desired maintenance dose
AE: NV, osteomalacia

42
Q

AEs of ASMs

A

CNS - somnolence, fatigue, dizziness, visual disturbances, nystagmus, ataxia

43
Q

Topiramate AE

A

Weight loss

Reduced speech fluency

44
Q

Managing AEs

A

Initiating therapy at low dose, slowly increasing
Avoiding large dosage changes
Restricting to monotherapy
Adjusting administration schedule

45
Q

Idiopathic AEs

A
Blood dyscrasia (aplastic anemia, agranulocytosis) 
Hepatotoxicity (1st gen) 
Pancreatitis (valproate) 
Lupus-like reaction 
Exfoliative dermatitis 
TEN/SJS
46
Q

Neurological AEs

A
Encephalopathy (high dose phenytoin, phenobarbitone) 
Pheripheral neuropathy (long term phenytoin, carbamazepine, phenobarbitone)
47
Q

Indications for ASM TDM

A

Establish individual’s therapeutic range
Assess lack of efficacy
Assess potential toxicity
Assess loss of efficacy (breakthrough seizures)

48
Q

Women of childbearing age

A

Potential risk to fetus via uncontrolled seizures and teratogenic potential
Lamotrigine

49
Q

Pregnancy and lactation

A

Referred to specialist care

Not an absolute contraindication to breastfeeding

50
Q

Discontinuation

A

Considered if min 2y seizure free
Longer than 2y if increased risk of seizure recurrence
Tapering schedule to be individualised

51
Q

Status Epilepticus windows

A

GTC: seizure > 5min, neuronal damage if > 30min

Treatment for SE once past 5min to prevent progression to > 30min

52
Q

SE Treatment

A
5-20min
IV Midazolam 
IV Lorazepam 
IV Diazepam 
20-40min 
IV Fosphenytoin
IV Valproic acid 
IV levetiracetam 
IV Phenobarbital